NetraMark Holdings (TSE:AIAI) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NetraMark Holdings Inc., a leader in AI software for clinical trial analytics, has reported significant progress in Q3, including the full commercialization of its proprietary AI platform validated by a major pharmaceutical company. They’ve refined their market strategy to focus on CNS and Oncology sectors and have secured a substantial client with over $10B USD market cap, resulting in four contracts. NetraMark’s AI technology aims to mitigate the high failure rates of clinical trials in the pharmaceutical industry by improving decision-making and potentially saving millions in investment.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue